Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia

NCT00520923 is registered in ClinicalTrials.gov with Denovo Biopharma LLC as lead sponsor.

NCT NCT00520923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00520923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia
Lead sponsor
Denovo Biopharma LLC
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
October 31, 2008
Enrollment
669 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia